Circulating Tumor Cells in Breast Cancer

Diana H. Liang, Carolyn Hall, Anthony Lucci

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

With active screening for early detection and advancements in treatment, there has been a significant decrease in mortality from breast cancer. However, a significant proportion of patients with non-metastatic breast cancer at time of diagnosis will relapse. Therefore, it is suggested that the dissemination of bloodstream tumor cells (circulating tumor cells, CTCs) undetectable by currently available diagnostic tools occurs during the early stages of breast cancer progression, and may be the potential source of micrometastases responsible for treatment failures. Here, we review the clinical significance of CTCs, as detected by the FDA-approved CellSearch® System, in both metastatic and non-metastatic breast cancer patients. Studies so far suggest that CTCs are prognostic of poorer outcomes in breast cancer patients; however, there is currently insufficient data to support use of CTC data to guide treatment. Therefore, there are ongoing studies to evaluate the utility of assessing CTC phenotypes to develop personalized breast cancer treatment, which will be reviewed in this chapter.

Original languageEnglish (US)
Title of host publicationRecent Results in Cancer Research
PublisherSpringer New York LLC
Pages127-145
Number of pages19
DOIs
StatePublished - Jan 1 2020

Publication series

NameRecent Results in Cancer Research
Volume215
ISSN (Print)0080-0015
ISSN (Electronic)2197-6767

Fingerprint

Circulating Neoplastic Cells
Breast Neoplasms
Neoplasm Micrometastasis
Treatment Failure
Therapeutics
Phenotype
Recurrence
Mortality
Neoplasms

Keywords

  • Biomarkers
  • Breast cancer
  • CTCs
  • Circulating tumor cells
  • Liquid biopsy
  • Micrometastases
  • Prognostic factors

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Liang, D. H., Hall, C., & Lucci, A. (2020). Circulating Tumor Cells in Breast Cancer. In Recent Results in Cancer Research (pp. 127-145). (Recent Results in Cancer Research; Vol. 215). Springer New York LLC. https://doi.org/10.1007/978-3-030-26439-0_7

Circulating Tumor Cells in Breast Cancer. / Liang, Diana H.; Hall, Carolyn; Lucci, Anthony.

Recent Results in Cancer Research. Springer New York LLC, 2020. p. 127-145 (Recent Results in Cancer Research; Vol. 215).

Research output: Chapter in Book/Report/Conference proceedingChapter

Liang, DH, Hall, C & Lucci, A 2020, Circulating Tumor Cells in Breast Cancer. in Recent Results in Cancer Research. Recent Results in Cancer Research, vol. 215, Springer New York LLC, pp. 127-145. https://doi.org/10.1007/978-3-030-26439-0_7
Liang DH, Hall C, Lucci A. Circulating Tumor Cells in Breast Cancer. In Recent Results in Cancer Research. Springer New York LLC. 2020. p. 127-145. (Recent Results in Cancer Research). https://doi.org/10.1007/978-3-030-26439-0_7
Liang, Diana H. ; Hall, Carolyn ; Lucci, Anthony. / Circulating Tumor Cells in Breast Cancer. Recent Results in Cancer Research. Springer New York LLC, 2020. pp. 127-145 (Recent Results in Cancer Research).
@inbook{9c79d341f73a4c5aacbd6d88c116a5e9,
title = "Circulating Tumor Cells in Breast Cancer",
abstract = "With active screening for early detection and advancements in treatment, there has been a significant decrease in mortality from breast cancer. However, a significant proportion of patients with non-metastatic breast cancer at time of diagnosis will relapse. Therefore, it is suggested that the dissemination of bloodstream tumor cells (circulating tumor cells, CTCs) undetectable by currently available diagnostic tools occurs during the early stages of breast cancer progression, and may be the potential source of micrometastases responsible for treatment failures. Here, we review the clinical significance of CTCs, as detected by the FDA-approved CellSearch{\circledR} System, in both metastatic and non-metastatic breast cancer patients. Studies so far suggest that CTCs are prognostic of poorer outcomes in breast cancer patients; however, there is currently insufficient data to support use of CTC data to guide treatment. Therefore, there are ongoing studies to evaluate the utility of assessing CTC phenotypes to develop personalized breast cancer treatment, which will be reviewed in this chapter.",
keywords = "Biomarkers, Breast cancer, CTCs, Circulating tumor cells, Liquid biopsy, Micrometastases, Prognostic factors",
author = "Liang, {Diana H.} and Carolyn Hall and Anthony Lucci",
year = "2020",
month = "1",
day = "1",
doi = "10.1007/978-3-030-26439-0_7",
language = "English (US)",
series = "Recent Results in Cancer Research",
publisher = "Springer New York LLC",
pages = "127--145",
booktitle = "Recent Results in Cancer Research",

}

TY - CHAP

T1 - Circulating Tumor Cells in Breast Cancer

AU - Liang, Diana H.

AU - Hall, Carolyn

AU - Lucci, Anthony

PY - 2020/1/1

Y1 - 2020/1/1

N2 - With active screening for early detection and advancements in treatment, there has been a significant decrease in mortality from breast cancer. However, a significant proportion of patients with non-metastatic breast cancer at time of diagnosis will relapse. Therefore, it is suggested that the dissemination of bloodstream tumor cells (circulating tumor cells, CTCs) undetectable by currently available diagnostic tools occurs during the early stages of breast cancer progression, and may be the potential source of micrometastases responsible for treatment failures. Here, we review the clinical significance of CTCs, as detected by the FDA-approved CellSearch® System, in both metastatic and non-metastatic breast cancer patients. Studies so far suggest that CTCs are prognostic of poorer outcomes in breast cancer patients; however, there is currently insufficient data to support use of CTC data to guide treatment. Therefore, there are ongoing studies to evaluate the utility of assessing CTC phenotypes to develop personalized breast cancer treatment, which will be reviewed in this chapter.

AB - With active screening for early detection and advancements in treatment, there has been a significant decrease in mortality from breast cancer. However, a significant proportion of patients with non-metastatic breast cancer at time of diagnosis will relapse. Therefore, it is suggested that the dissemination of bloodstream tumor cells (circulating tumor cells, CTCs) undetectable by currently available diagnostic tools occurs during the early stages of breast cancer progression, and may be the potential source of micrometastases responsible for treatment failures. Here, we review the clinical significance of CTCs, as detected by the FDA-approved CellSearch® System, in both metastatic and non-metastatic breast cancer patients. Studies so far suggest that CTCs are prognostic of poorer outcomes in breast cancer patients; however, there is currently insufficient data to support use of CTC data to guide treatment. Therefore, there are ongoing studies to evaluate the utility of assessing CTC phenotypes to develop personalized breast cancer treatment, which will be reviewed in this chapter.

KW - Biomarkers

KW - Breast cancer

KW - CTCs

KW - Circulating tumor cells

KW - Liquid biopsy

KW - Micrometastases

KW - Prognostic factors

UR - http://www.scopus.com/inward/record.url?scp=85073168893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073168893&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-26439-0_7

DO - 10.1007/978-3-030-26439-0_7

M3 - Chapter

C2 - 31605227

AN - SCOPUS:85073168893

T3 - Recent Results in Cancer Research

SP - 127

EP - 145

BT - Recent Results in Cancer Research

PB - Springer New York LLC

ER -